Consulting Services for Private Equity/Venture Capital Firms
Commercial Due Diligence
Commercial due diligence covering market dynamics, price-volume trends, market growth, key purchase criteria, competitive positioning of target company and product portfolio, review of management business plan and growth strategy.
We have successfully executed commercial due diligence in following healthcare segments:
- Medical devices and equipment
- Pharma CDMOs and CROs
- MedTech contract manufacturing
- Healthcare IT
- Specialty Pharmaceuticals
- Branded and unbranded generics
We also offer early due diligence services to enable our Private Equity clients to make go, no-go decisions in a timely and cost-effective manner.
View Case Study
Proprietary Deal Generation
Leading Private Equity investors understand the need to generate proprietary deals.
We leverage our deep knowledge of healthcare sector to help clients generate proprietary deals through a process of
- Generating a comprehensive mapping of relevant companies
- Identifying potential targets that fit investor criteria
- Supporting investors in tracking/contacting identified target companies
Our rigorous methodology and ‘two set of eyes’ quality approach has enabled private equity firms to generate proprietary deals for their platform and add-on investments in following segments:
- Healthcare IT
- Physician practices including dentists, ASCs, physiotherapy, dermatology, cardiology, GPs, veterinary, behavioral health clinics
- CROs, CDMOs
- Professional service organizations in regulatory, medical communications, consulting among others
- Add-on deals in medical devices, specialty pharma
View Case Study
Sector Reviews
Our deep healthcare expertise has resulted in successful engagements with private equity firms to conduct comprehensive strategic reviews in chosen segments.
Our sector reviews cover
- Industry (demand side and supply side) dynamics and challenges
- Market sizing and growth
- Product pools and value chain analysis
- Level of differentiation in the segment
- Regulatory and reimbursement overview
- Future outlook in terms of growth, profitability for investors
- Key target companies and their ‘outside-in’ profiles
View Case Study
